Capstan Therapeutics to Participate in Upcoming Industry Conferences

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)-- Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the following upcoming industry conferences:

Jefferies Cell and Genetic Medicine Summit
Date: Tuesday, September 26, 2023
Time: 12:45 p.m. EDT
Location: New York, NY

Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will participate in a virtual panel discussion titled “CAR T Beyond Cancer.”

2023 Cell & Gene Meeting on the Mesa
Date: Tuesday, October 10, 2023
Time: 9:30 a.m. PT
Location: Rentschler ATMP Ballroom at the Park Hyatt Aviara Resort in Carlsbad, CA

Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will give a company presentation.

BMO Biopharma Spotlight Series: (R)Evolution of RNA Therapies
Date: Tuesday, October 10, 2023
Location: Virtual

Company management will participate in 1:1 investor meetings.

Leerink Partners Biopharma Private Company Connect
Date: Wednesday, October 25 – Thursday, October 26, 2023
Location: Virtual

Company management will participate in 1:1 investor meetings.

About Capstan (www.capstantx.com)

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230926471695/en/

Investors:
Miguel Arcinas
Vice President of Corporate Development
Capstan Therapeutics
[email protected]

Media:
Rhiannon Jeselonis
Ten Bridge Communications
[email protected]

Source: Capstan Therapeutics, Inc.

You May Also Be Interested In

• Barings Global Short Duration High Yield Fund Announces October 2026 Monthly Distribution of $0.1223 per Share
• Newmont Capital Group Highlights No Fees for Life IRA Program for Qualifying Customers
• Indianapolis AI Child Exploitation Charges Highlight Growing Crisis for Families, Says Potts Law Firm